Search Results - Jay Mei

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    1190 A novel ‘2+1’bispecific T cell engager platform, enables enhanced anti-tumor activity with reduced risk of CRS by Tengteng Li, Hui Yuwen, Bing Hou, Jay Mei, Bo Shan, Yijing Ren

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  2. 2

    1191 ATG-021, a novel 2+1 CD3-based T cell engager (TCE) targeting GPRC5D, demonstrates potent in vivo anti-tumor efficacy with low cytokine release by Tengteng Li, Hui Yuwen, Bing Hou, Jay Mei, Bo Shan, Yijing Ren

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  3. 3

    1112 Single-cell RNA sequencing reveals the positive feedback activation loop between T and dendritic cells induced by PD-L1x4–1BB bispecific antibody by Linjie Tian, Hui Yuwen, Bing Hou, Jay Mei, Bo Shan, Yunkai Zhang, Gang Bian, Ao Sun

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  4. 4

    1391 Antibody targeting a specific epitope of LILRB4 induces potent ADCC/ADCP effect against leukemia cells by Peng Chen, Bing Hou, Jay Mei, Bo Shan, Ao Sun, Enlin Zheng, Mengshi Gao, Suya Bai

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  5. 5

    Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or... by Meletios A. Dimopoulos, Michel Delforge, Roman Hájek, Martin Kropff, Maria T. Petrucci, Philip Lewis, Annabel Nixon, Jingshan Zhang, Jay Mei, Antonio Palumbo

    Published in Haematologica (2013-05-01)
    Get full text
    Article


  6. 6

    1337 The preclinical characterization and translational research of ATG-031, a first-in-class humanized anti-CD24 antibody, for the treatment of solid tumors and hematological mali... by Jishun Chen, Min Deng, Yun Liu, Peng Chen, Linjie Tian, Rong Guo, Bing Hou, Jay Mei, Bo Shan, Yunkai Zhang, Jiamei Luo

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  7. 7

    Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia by Jennifer R. Brown, Wael A. Harb, Brian T. Hill, Janice Gabrilove, Jeff P. Sharman, Marshall T. Schreeder, Paul M. Barr, James M. Foran, Thomas P. Miller, Jan A. Burger, Kevin R. Kelly, Daruka Mahadevan, Shuo Ma, Yan Li, Daniel W. Pierce, Evelyn Barnett, Jeffrey Marine, Monika Miranda, Ada Azaryan, Xujie Yu, Pilar Nava-Parada, Jay Mei, Thomas J. Kipps

    Published in Haematologica (2016-07-01)
    Get full text
    Article


Search Tools: